Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
T-Mobile US
TMUS
|
$576M |
| 2 |
AbbVie
ABBV
|
$478M |
| 3 |
Snap
SNAP
|
$318M |
| 4 |
Boston Scientific
BSX
|
$284M |
| 5 |
Lam Research
LRCX
|
$260M |
Top Sells
| 1 |
Boeing
BA
|
$389M |
| 2 |
Alphabet (Google) Class C
GOOG
|
$309M |
| 3 |
AMTD
TD Ameritrade Holding Corp
AMTD
|
$284M |
| 4 |
Shopify
SHOP
|
$240M |
| 5 |
Sysco
SYY
|
$217M |
Sector Composition
| 1 | Technology | 30.65% |
| 2 | Healthcare | 19.7% |
| 3 | Consumer Discretionary | 10.82% |
| 4 | Financials | 9.88% |
| 5 | Communication Services | 8.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
Acadia Pharmaceuticals
ACAD
$4.26B
| $190M | 0.11% |
3,909,963
+2,420,061
| +162% | +$117M |
|
202
Synchrony
SYF
$28.1B
| $189M | 0.11% |
8,547,291
+450,483
| +6% | +$9.98M |
|
203
VF Corp
VFC
$5.86B
| $185M | 0.1% |
3,027,634
-220,369
| -7% | -$13.4M |
|
204
Visteon
VC
$3.41B
| $184M | 0.1% |
2,691,299
-172,706
| -6% | -$11.8M |
|
205
Clarivate
CLVT
$2.96B
| $184M | 0.1% |
8,249,476
-850,885
| -9% | -$19M |
|
206
Regeneron Pharmaceuticals
REGN
$60.8B
| $184M | 0.1% |
295,015
+257,084
| +678% | +$160M |
|
207
Dynatrace
DT
$15.1B
| $183M | 0.1% |
+4,505,188
| New | +$183M |
|
208
Quest Diagnostics
DGX
$20.5B
| $182M | 0.1% |
1,597,951
+599,125
| +60% | +$68.3M |
|
209
Casey's General Stores
CASY
$18.8B
| $181M | 0.1% |
1,213,550
+109,402
| +10% | +$16.4M |
|
210
Pfizer
PFE
$141B
| $180M | 0.1% |
5,818,447
-457,302
| -7% | -$14.2M |
|
211
Blackbaud
BLKB
$3.23B
| $180M | 0.1% |
3,157,948
-144,319
| -4% | -$8.24M |
|
212
RenaissanceRe
RNR
$11.3B
| $180M | 0.1% |
1,053,452
-152,049
| -13% | -$26M |
|
213
Ligand Pharmaceuticals
LGND
$3.25B
| $180M | 0.1% |
2,572,773
+21,467
| +0.8% | +$1.5M |
|
214
Amicus Therapeutics
FOLD
$2.46B
| $178M | 0.1% |
11,793,759
+167,835
| +1% | +$2.53M |
|
215
Veeva Systems
VEEV
$44.7B
| $177M | 0.1% |
754,192
+314,853
| +72% | +$73.8M |
|
216
Guidewire Software
GWRE
$22B
| $175M | 0.1% |
1,580,673
+8,233
| +0.5% | +$913K |
|
217
DexCom
DXCM
$31.6B
| $171M | 0.1% |
1,691,580
-1,448,388
| -46% | -$147M |
|
218
MSCI
MSCI
$42.9B
| $170M | 0.1% |
509,449
-315,746
| -38% | -$105M |
|
219
Nordson
NDSN
$12.6B
| $168M | 0.09% |
888,047
-235,177
| -21% | -$44.6M |
|
220
Parker-Hannifin
PH
$96.1B
| $168M | 0.09% |
918,974
-239,034
| -21% | -$43.8M |
|
221
Garmin
GRMN
$45.7B
| $168M | 0.09% |
1,727,327
+192,481
| +13% | +$18.8M |
|
222
Baxter International
BAX
$12.5B
| $167M | 0.09% |
1,935,905
-243,630
| -11% | -$21M |
|
223
ServiceNow
NOW
$190B
| $166M | 0.09% |
408,802
-9,975
| -2% | -$4.04M |
|
224
Trade Desk
TTD
$25.5B
| $165M | 0.09% |
4,067,790
-450,860
| -10% | -$18.3M |
|
|
ENV
225
DELISTED
ENVESTNET, INC.
ENV
| $165M | 0.09% |
2,243,334
-189,429
| -8% | -$13.9M |
|